Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

Increased parenchymal damage and steatohepatitis in Caucasian non-alcoholic fatty liver disease patients with common IL1B and IL6 polymorphisms.

Nelson JE, Handa P, Aouizerat B, Wilson L, Vemulakonda LA, Yeh MM, Kowdley KV; NASH Clinical Research Network..

Aliment Pharmacol Ther. 2016 Dec;44(11-12):1253-1264. doi: 10.1111/apt.13824. Epub 2016 Oct 11.

PMID:
27730688
2.

Improvement in liver histology is associated with reduction in dyslipidemia in children with nonalcoholic fatty liver disease.

Corey KE, Vuppalanchi R, Vos M, Kohli R, Molleston JP, Wilson L, Unalp-Arida A, Cummings OW, Lavine JE, Chalasani N; Nonalcoholic Steatohepatitis Clinical Research Network..

J Pediatr Gastroenterol Nutr. 2015 Mar;60(3):360-7. doi: 10.1097/MPG.0000000000000584.

3.

Longitudinal assessment of high blood pressure in children with nonalcoholic fatty liver disease.

Schwimmer JB, Zepeda A, Newton KP, Xanthakos SA, Behling C, Hallinan EK, Donithan M, Tonascia J; Nonalcoholic Steatohepatitis Clinical Research Network..

PLoS One. 2014 Nov 24;9(11):e112569. doi: 10.1371/journal.pone.0112569. eCollection 2014.

4.

Histological abnormalities in children with nonalcoholic fatty liver disease and normal or mildly elevated alanine aminotransferase levels.

Molleston JP, Schwimmer JB, Yates KP, Murray KF, Cummings OW, Lavine JE, Brunt EM, Scheimann AO, Unalp-Arida A; NASH Clinical Research Network..

J Pediatr. 2014 Apr;164(4):707-713.e3. doi: 10.1016/j.jpeds.2013.10.071. Epub 2013 Dec 19.

5.

Vitamin E and changes in serum alanine aminotransferase levels in patients with non-alcoholic steatohepatitis.

Hoofnagle JH, Van Natta ML, Kleiner DE, Clark JM, Kowdley KV, Loomba R, Neuschwander-Tetri BA, Sanyal AJ, Tonascia J; Non-alcoholic Steatohepatitis Clinical Research Network (NASH CRN)..

Aliment Pharmacol Ther. 2013 Jul;38(2):134-43. doi: 10.1111/apt.12352. Epub 2013 May 29.

6.

Lower serum hepcidin and greater parenchymal iron in nonalcoholic fatty liver disease patients with C282Y HFE mutations.

Nelson JE, Brunt EM, Kowdley KV; Nonalcoholic Steatohepatitis Clinical Research Network..

Hepatology. 2012 Nov;56(5):1730-40. doi: 10.1002/hep.25856. Epub 2012 Sep 20.

7.

Association between puberty and features of nonalcoholic fatty liver disease.

Suzuki A, Abdelmalek MF, Schwimmer JB, Lavine JE, Scheimann AO, Unalp-Arida A, Yates KP, Sanyal AJ, Guy CD, Diehl AM; Nonalcoholic Steatohepatitis Clinical Research Network..

Clin Gastroenterol Hepatol. 2012 Jul;10(7):786-94. doi: 10.1016/j.cgh.2012.01.020. Epub 2012 Feb 14.

8.

Hedgehog pathway activation parallels histologic severity of injury and fibrosis in human nonalcoholic fatty liver disease.

Guy CD, Suzuki A, Zdanowicz M, Abdelmalek MF, Burchette J, Unalp A, Diehl AM; NASH CRN..

Hepatology. 2012 Jun;55(6):1711-21. doi: 10.1002/hep.25559. Epub 2012 Apr 18.

9.

Correlation of vitamin E, uric acid, and diet composition with histologic features of pediatric NAFLD.

Vos MB, Colvin R, Belt P, Molleston JP, Murray KF, Rosenthal P, Schwimmer JB, Tonascia J, Unalp A, Lavine JE; NASH CRN Research Group..

J Pediatr Gastroenterol Nutr. 2012 Jan;54(1):90-6. doi: 10.1097/MPG.0b013e318229da1a.

10.

Costaining for keratins 8/18 plus ubiquitin improves detection of hepatocyte injury in nonalcoholic fatty liver disease.

Guy CD, Suzuki A, Burchette JL, Brunt EM, Abdelmalek MF, Cardona D, McCall SJ, Ünalp A, Belt P, Ferrell LD, Diehl AM; Nonalcoholic Steatohepatitis Clinical Research Network..

Hum Pathol. 2012 Jun;43(6):790-800. doi: 10.1016/j.humpath.2011.07.007. Epub 2011 Oct 28.

11.

Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings.

Brunt EM, Kleiner DE, Wilson LA, Belt P, Neuschwander-Tetri BA; NASH Clinical Research Network (CRN)..

Hepatology. 2011 Mar;53(3):810-20. doi: 10.1002/hep.24127. Epub 2011 Feb 11.

12.

Physical activity recommendations, exercise intensity, and histological severity of nonalcoholic fatty liver disease.

Kistler KD, Brunt EM, Clark JM, Diehl AM, Sallis JF, Schwimmer JB; NASH CRN Research Group..

Am J Gastroenterol. 2011 Mar;106(3):460-8; quiz 469. doi: 10.1038/ajg.2010.488. Epub 2011 Jan 4.

13.

Increased fructose consumption is associated with fibrosis severity in patients with nonalcoholic fatty liver disease.

Abdelmalek MF, Suzuki A, Guy C, Unalp-Arida A, Colvin R, Johnson RJ, Diehl AM; Nonalcoholic Steatohepatitis Clinical Research Network..

Hepatology. 2010 Jun;51(6):1961-71. doi: 10.1002/hep.23535.

14.

Symptoms and quality of life in obese children and adolescents with non-alcoholic fatty liver disease.

Kistler KD, Molleston J, Unalp A, Abrams SH, Behling C, Schwimmer JB; Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN)..

Aliment Pharmacol Ther. 2010 Feb 1;31(3):396-406. doi: 10.1111/j.1365-2036.2009.04181.x. Epub 2009 Oct 23.

15.

Treatment of nonalcoholic fatty liver disease in children: TONIC trial design.

Lavine JE, Schwimmer JB, Molleston JP, Scheimann AO, Murray KF, Abrams SH, Rosenthal P, Sanyal AJ, Robuck PR, Brunt EM, Unalp A, Tonascia J; Nonalcoholic Steatohepatitis Clinical Research Network Research Group..

Contemp Clin Trials. 2010 Jan;31(1):62-70. doi: 10.1016/j.cct.2009.09.001. Epub 2009 Sep 15.

Supplemental Content

Loading ...
Support Center